Therapeutics

Displaying 21 - 23 of 23


New Drug for Blood Clot: FXII Inhibitors to Treat Thrombosis

Thrombosis is the formation of a blood clot inside a blood vessel, which may cause reduced blood flow to a tissue, or even tissue death. Thrombosis, inflammation, and infections are responsible for >70% of all human mortality. Thrombosis is also the major factor for heart disease and stroke. 500,000 die from thrombosis every year in Europe. Inhibitory treatment of these conditions may also improve the outcomes of several non-fatal diseases. Researchers from Vanderbilt University and Oregon Health & Science University have jointly discovered new monoclonal antibodies that potently inhibit the blood coagulation protein factor XII (FXII), a critical player in the pathway, and anticoagulate blood. This invention provides foundation for commercial development of anti-thrombotic drugs based on new molecular entities.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Antibody
Assays/Screening

Antimicrobial Compounds and Methods of Use Thereof

Vanderbilt researchers, led by Eric Skaar, Ph.D., have identified novel compounds that are antimicrobial. These compounds represent a first in class as they target a new bacterial pathway that has never been targeted as an antimicrobial strategy.


Licensing Contact

Karen Rufus

615.322.4295
Therapeutics

Prevention of Cytokine Induced Apoptosis In Intestinal Epithelial Cells By A Probiotic Bacterium

The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient.


Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Brent Polk, Fang Yan
Therapeutics
Gastrointestinal
Protein/Peptide